| Autor: |
Ashley S. Felix, Kristen Bunch, Hannah P. Yang, Hannah Arem, Britton Trabert, Gretchen L. Gierach, Yikyung Park, William J. Lowery, Louise A. Brinton |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Gynecologic Oncology Reports, Vol 13, Iss C, Pp 13-17 (2015) |
| Druh dokumentu: |
article |
| ISSN: |
2352-5789 |
| DOI: |
10.1016/j.gore.2015.04.007 |
| Popis: |
Background: Although menopausal hormone therapy (MHT) use has been linked with an increased risk of ovarian cancer, whether pre-diagnosis MHT use affects ovarian cancer-specific mortality is unknown. Methods: Our analysis included 395 incident epithelial ovarian cancer patients with data on pre-diagnosis MHT use from the National Institutes of Health-AARP (NIH-AARP) Diet and Health Study. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for MHT type and ovarian cancer-specific mortality, adjusted for tumor characteristics, treatment, and other risk factors. Effect modification by histology (serous vs. non-serous) was examined using likelihood ratio tests comparing models with and without interaction terms between MHT type and histology. Results: Ovarian cancer-specific mortality was not associated with pre-diagnosis estrogen-only therapy (ET) (HR = 1.09, 95% CI = 0.70–1.68) or estrogen plus progestin-only therapy (EPT) (HR = 0.97, 95% CI = 0.68–1.38). Neither recency of use nor specific regimen of EPT-only (sequential vs. continuous) was related to mortality. In analyses stratified by histology, no significant association between MHT type and ovarian cancer-specific mortality was observed among serous or non-serous cases; however, a significant interaction between MHT type and histology was noted (p-heterogeneity = 0.01). Conclusion: Our results suggest that pre-diagnosis MHT use is not related to risk of ovarian cancer-specific death. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
